Mainz Biomed Valuation

Is MYNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MYNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MYNZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MYNZ's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MYNZ?

Key metric: As MYNZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MYNZ. This is calculated by dividing MYNZ's market cap by their current revenue.
What is MYNZ's PS Ratio?
PS Ratio6.3x
SalesUS$917.20k
Market CapUS$5.29m

Price to Sales Ratio vs Peers

How does MYNZ's PS Ratio compare to its peers?

The above table shows the PS ratio for MYNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average21.2x
ONVO Organovo Holdings
63.7x43.8%US$6.5m
ORGS Orgenesis
6.6xn/aUS$6.3m
MRZM Marizyme
14.4xn/aUS$5.3m
SBFM Sunshine Biopharma
0.2xn/aUS$4.9m
MYNZ Mainz Biomed
6.3x81.8%US$5.3m

Price-To-Sales vs Peers: MYNZ is good value based on its Price-To-Sales Ratio (6.3x) compared to the peer average (21.2x).


Price to Sales Ratio vs Industry

How does MYNZ's PS Ratio compare vs other companies in the US Biotechs Industry?

126 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.4x1.3%US$23.13b
MRNA Moderna
3.2x6.7%US$16.80b
INCY Incyte
3.5x9.0%US$14.16b
ALKS Alkermes
3.1x-0.7%US$4.75b
MYNZ 6.3xIndustry Avg. 9.9xNo. of Companies126PS01632486480+
126 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MYNZ is good value based on its Price-To-Sales Ratio (6.3x) compared to the US Biotechs industry average (9.4x).


Price to Sales Ratio vs Fair Ratio

What is MYNZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MYNZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.3x
Fair PS Ratio19.6x

Price-To-Sales vs Fair Ratio: MYNZ is good value based on its Price-To-Sales Ratio (6.3x) compared to the estimated Fair Price-To-Sales Ratio (19.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies